We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Genedrive Plc | LSE:GDR | London | Ordinary Share | GB00B1VKB244 | ORD 1.5P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| -0.025 | -1.37% | 1.80 | 567,619 | 10:42:42 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 1.75 | 1.85 | 1.825 | 1.80 | 1.825 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Coml Physical, Biologcl Resh | 501k | -7.08M | -0.0130 | -1.38 | 9.91M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 16:48:19 | O | 50,000 | 1.80 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 17/3/2025 | 11:04 | UK RNS | Genedrive PLC Scottish Government testing programme investment |
| 14/3/2025 | 07:00 | UK RNS | Genedrive PLC CYP2C19-ID Kit adopted for routine clinical use |
| 30/12/2024 | 11:54 | UK RNS | Genedrive PLC Result of AGM |
| 27/12/2024 | 11:51 | ALNC |  Genedrive shares rise on positive results for genetic testing kit |
| 27/12/2024 | 07:00 | UK RNS | Genedrive PLC Genedrive® CYP2C19-ID Kit performance published |
| 20/12/2024 | 12:16 | UK RNS | Genedrive PLC Grant of Options |
| 20/12/2024 | 12:12 | UK RNS | Genedrive PLC Director/PDMR Shareholding |
| 05/12/2024 | 15:00 | UK RNS | Genedrive PLC Posting of annual report and notice of AGM |
| 29/11/2024 | 13:00 | UK RNS | Genedrive PLC Block listing returns |
| 29/11/2024 | 10:18 | ALNC | Genedrive annual loss widens due to increased expenses |
Genedrive (GDR) Share Charts1 Year Genedrive Chart |
|
1 Month Genedrive Chart |
Intraday Genedrive Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 21/3/2025 | 08:32 | Genedrive, A Game Changer for Point of Care Testing Market? | 10,512 |
| 17/3/2025 | 12:22 | GENEDRIVE PLC | 966 |
| 16/12/2024 | 14:30 | GENEDRIVE MODERATED | 1,042 |
| 01/9/2024 | 13:10 | TO DATE THEIR KITS HAVE REVENUES OF ONLY Ј100K.GET OUT!! | 38 |
| 08/8/2024 | 07:30 | Shares are poised to rebound very strongly | 1,248 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 16:48:20 | 1.80 | 50,000 | 900.00 | O |
| 16:26:34 | 1.83 | 109,098 | 1,996.49 | O |
| 16:25:26 | 1.78 | 92,361 | 1,645.41 | O |
| 16:16:37 | 1.75 | 155 | 2.71 | O |
| 16:16:37 | 1.85 | 308 | 5.70 | O |
| Top Posts |
|---|
Posted at 21/3/2025 08:20 by Genedrive Daily Update Genedrive Plc is listed in the Coml Physical, Biologcl Resh sector of the London Stock Exchange with ticker GDR. The last closing price for Genedrive was 1.83p.Genedrive currently has 543,141,481 shares in issue. The market capitalisation of Genedrive is £9,776,547. Genedrive has a price to earnings ratio (PE ratio) of -1.38. This morning GDR shares opened at 1.83p |
Posted at 14/3/2025 07:06 by bones698 Wow 900 patients per annum that's going to put gdr on the map lol . Unfortunately the NHS is a slow lumbering animal and it seems the concerns are correct that gdr will have to deal with every hospital to get their system through the door making it time consuming and very long winded .Almost 9 months effort to get 900 patients more isn't going to cut it . Another raise will be needed soon and that will see the share price crash lower . Glad I got out when I did as progress is almost none existent |
Posted at 28/11/2024 11:45 by z1co There will be no placing for the foreseeable future ,the company has than enough money until Q4 2025.Stephen11 on the lse chat thinks the same: Here's how i'm seeing the cash runway, with forward looking figures and RNS info to support my hypothesis. We will receive an £800,000 tax credit early next year, in addition to the £500,000 indicated in this weeks RNS. This should give us an extra 3 months (approx). GDR proposed a cash raise of £6m last May 2024, and this money was approved and received in June 2024. From the fundraise, and assuming a monthly cash burn of between £400,000 to £450,000 we are funded to between July to September 2025. Add the extra £1.3m (tax credit and order) and we are funded to somewhere between September to December 2025. Additionally, the major data collections, used to support NHS commissioning will end around Jan to April 2025. So, there is a high likelihood that we will have a national rollout of one or both products on or before these dates. This will generate significant commercial traction, and will also increase the share price - any fundraise next year will look totally different to that off June 2024. For a start the share price could be 10-15p. Therefore, the possibility of a commercial loan could be considered |
Posted at 27/11/2024 15:04 by z1co Roger is a deramper just like Batiatus and he also posts porkies:There will be no placing for the foreseeable future ,the company has than enough money until Q4 2025. Stephen11 on the lse chat thinks the same: Here's how i'm seeing the cash runway, with forward looking figures and RNS info to support my hypothesis. We will receive an £800,000 tax credit early next year, in addition to the £500,000 indicated in this weeks RNS. This should give us an extra 3 months (approx). GDR proposed a cash raise of £6m last May 2024, and this money was approved and received in June 2024. From the fundraise, and assuming a monthly cash burn of between £400,000 to £450,000 we are funded to between July to September 2025. Add the extra £1.3m (tax credit and order) and we are funded to somewhere between September to December 2025. Additionally, the major data collections, used to support NHS commissioning will end around Jan to April 2025. So, there is a high likelihood that we will have a national rollout of one or both products on or before these dates. This will generate significant commercial traction, and will also increase the share price - any fundraise next year will look totally different to that off June 2024. For a start the share price could be 10-15p. Therefore, the possibility of a commercial loan could be considered |
Posted at 24/11/2024 15:59 by batiatus You always have to have the last say dont you HazlJust admit you have made a bad investment where you had anticipated sales and FDA on the news front, but it hasn't come. You were expecting the share price to go up to 5p. You and Z1co had been banging on about it since June, where is the share price now? Let me remind you, the share price is lower after the NICE recommendation news in July. |
Posted at 19/11/2024 07:34 by m_night10 POLX Polarean Imaging 1.6p I fancy to fill the gap to 3.2p and head to 10p+. Mcap is peanuts and cash position is much longer to Q2 2026 and revenue are higher and growing even more quickly than this.. I see it as a steal for the FDA approved Xenon MRI. No company debt, masssive growth potential in the worlds biggest health market the United States where it's already in 21 clinical settings, best in class next generation MRI. Revenues rising up 3000% to $3mil for 2024 and doubling again next to $6mil in 2025 Cash runway to minimum of Q2 2026, looks set to be extended given revenues ahead of expectations.Putting this UK recovery play potential on radars as used to trade at 100p and has made significant commercial progress since FDA approval. Massive takeover target and will be sold for 20p+ share price. 1. September 18th 2024: Interventional radiology vendor Merit Medical to acquire device portfolio for $210M. APPROX 13P SHARE PRICE EQUIVALENT FOR POLX 2. September 25th 2024: Private equity firm acquiring diagnostic imaging provider for $658M APPROX 48P SHARE PRICE EQUIVALENT FOR POLX 3. October 14th 2024: Hologic to Acquire Gynesonics The women’s health company will be purchased for approximately $350 million. APPROX 22P SHARE PRICE EQUIVALENT FOR POLX 4. Bracco current major TR1 Holder of Polarean splashed out $450MILLION for a diagnostic buyout POLX easy buyout target more massive premiums as per the above imv. DYOR, not advice. |
Posted at 14/11/2024 07:29 by m_night10 POLX Polarean Imaging about to break out above 2p soon. Mcap is peanuts and cash position is much longer to Q2 2026 and revenue are higher and growing even more quickly than this.. I see it as a steal for the FDA approved Xenon MRI. No company debt, masssive growth potential in the worlds biggest health market the United States where it's already in 21 clinical settings, best in class next generation MRI. Revenues rising up 3000% to $3mil for 2024 and doubling again next to $6mil. 1.55p and gap at over 3p. ATH 100p. Cash runway to minimum of Q2 2026, looks set to be extended given revenues ahead of expectations.Putting this UK recovery play potential on radars. 1. September 18th 2024: Interventional radiology vendor Merit Medical to acquire device portfolio for $210M. APPROX 13P SHARE PRICE EQUIVALENT FOR POLX 2. September 25th 2024: Private equity firm acquiring diagnostic imaging provider for $658M APPROX 48P SHARE PRICE EQUIVALENT FOR POLX 3. October 14th 2024: Hologic to Acquire Gynesonics The women’s health company will be purchased for approximately $350 million. APPROX 22P SHARE PRICE EQUIVALENT FOR POLX 4. Bracco current major TR1 Holder of Polarean splashed out $450MILLION for a diagnostic buyout POLX easy buyout target more massive premiums as per the above imv. DYOR, not advice. |
Posted at 12/11/2024 19:02 by m_night10 POLX Polarean Imaging about to break out above 2p soon. Mcap is peanuts and cash position is much longer to Q2 2026 and revenue are higher and growing even more quickly than this.. I see it as a steal for the FDA approved Xenon MRI. No company debt, masssive growth potential in the worlds biggest health market the United States where it's already in 21 clinical settings, best in class next generation MRI. Revenues rising up 3000% to $3mil for 2024 and doubling again next to $6mil. 155p and gap at over 3p. ATH 100p. Cash runway to minimum of Q2 2026, looks set to be extended given revenues ahead of expectations.Putting this UK recovery play potential on radars. 1. September 18th 2024: Interventional radiology vendor Merit Medical to acquire device portfolio for $210M. APPROX 13P SHARE PRICE EQUIVALENT FOR POLX 2. September 25th 2024: Private equity firm acquiring diagnostic imaging provider for $658M APPROX 48P SHARE PRICE EQUIVALENT FOR POLX 3. October 14th 2024: Hologic to Acquire Gynesonics The women’s health company will be purchased for approximately $350 million. APPROX 22P SHARE PRICE EQUIVALENT FOR POLX 4. Bracco current major TR1 Holder of Polarean splashed out $450MILLION for a diagnostic buyout POLX easy buyout target more massive premiums as per the above imv. DYOR, not advice. |
Posted at 12/11/2024 10:12 by hazl Good to see GDR share price fighting against the low start.That was due in part to the UT trade at close yesterday, in my opinion . IMO |
Posted at 12/11/2024 07:50 by m_night10 POLX Polarean Imaging will break out above 2p soon. Mcap only $20mil. I see it as a steal for the FDA approved Xenon MRI. No company debt, masssive growth potential in the worlds biggest health market the United States where it's already in 21 clinical settings, best in class next generation MRI. Revenues rising up 3000% to $3mil for 2024 and doubling again next to $6mil. 1.55p and gap at over 3p. ATH 100p. Cash runway to minimum of Q1 2026, looks set to be extended given revenues ahead of expectations.Putting this UK recovery play potential on radars. 1. September 18th 2024: Interventional radiology vendor Merit Medical to acquire device portfolio for $210M. APPROX 13P SHARE PRICE EQUIVALENT FOR POLX 2. September 25th 2024: Private equity firm acquiring diagnostic imaging provider for $658M APPROX 48P SHARE PRICE EQUIVALENT FOR POLX 3. October 14th 2024: Hologic to Acquire Gynesonics The women’s health company will be purchased for approximately $350 million. APPROX 22P SHARE PRICE EQUIVALENT FOR POLX 4. Bracco current major TR1 Holder of Polarean splashed out $450MILLION for a diagnostic buyout POLX easy buyout target imv. DYOR, not advice. |
Posted at 08/11/2024 07:29 by m_night10 POLX about to break out above 2p. I see it as a steal for the FDA approvedXenon MRI. No company debt, masssive growth potential in the worlds biggest health market the United States where it's already in 21 clinical settings, best in class next generation MRI. Revenues rising up 3000% to $3mil for 2024 and doubling again next to $6mil. 1.65p and gap at over 3p. Cash runway to minimum of Q1 2026, looks set to be extended given revenues ahead of expectations.Similar set up to GDR before it filled it's gap. 1. September 18th 2024: Interventional radiology vendor Merit Medical to acquire device portfolio for $210M. APPROX 13P SHARE PRICE EQUIVALENT FOR POLX 2. September 25th 2024: Private equity firm acquiring diagnostic imaging provider for $658M APPROX 48P SHARE PRICE EQUIVALENT FOR POLX 3. October 14th 2024: Hologic to Acquire Gynesonics The women’s health company will be purchased for approximately $350 million. APPROX 22P SHARE PRICE EQUIVALENT FOR POLX 4. Bracco current major TR1 Holder of Polarean splashed out $450MILLION for a diagnostic buyout POLX easy buyout target imv. DYOR. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
